What does leap Therapeutics do?

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer.

What is leap Therapeutics (LPTx)?

Leap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap’s most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. DKN-01 is being developed in patients with esophagogastric, gynecologic, and colorectal cancers.

Where is leap Therapeutics headquartered?

Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. The company was founded on January 3, 2011 and is headquartered in Cambridge, MA. LPTX | Complete Leap Therapeutics Inc. stock news by MarketWatch.